Zobrazeno 21 - 30
of 72
pro vyhledávání: '"Iris Schrader"'
Autor:
Nadia Harbeck, Dennis Rokitta, Iris Schrader, Mathias Warm, Bernd Gerber, Holger Eidtmann, B. Conrad, Uwe Fuhr, Gunter von Minckwitz, K. Schwedler, Sibylle Loibl, Michaela Wüllner, Keyur Mehta
Publikováno v:
Breast Care. 9:169-174
Background: Sorafenib was tested for neoadjuvant treatment with an anthracycline/taxane-based chemotherapy in the open-label, multicentre, single-arm phase II study, ‘SOFIA'. Patients and Methods: Inclusion criteria were: HER2 negative, cT3, cT4 or
Autor:
Helmut Forstbauer, Wolfgang Janni, Hans Tesch, D. M. Zahm, Brigitte Rack, D Finas, U Soeling, Iris Schrader, J Hucke, Mahdi Rezai, Thomas L. Beck, Philip Hepp, E. Weiss, M. W. Beckmann, A. Kleine-Tebbe
Publikováno v:
Cancer Research. 72:P2-10
Background: MUC1 based tumor markers like CA27.29 (TM) in breast cancer are routinely used in metastatic disease as early marker for treatment efficacy. However, in early stage disease data is sparse. In this analysis, we looked at the impact of indi
Autor:
Berit Maria Müller, Jens-Uwe Blohmer, Christine Solbach, Iris Schrader, Georg Kunz, Holm Eggemann, Claus Hanusch, Bernd Gerber, Holger Eidtmann, Peter A. Fasching, Christian Jackisch, Jens Huober, Carsten Denkert, Valentina Nekljudova, Gunter von Minckwitz, K Kittel, Sibylle Loibl, Michael Untch, Rolf Kreienberg, Maik Hauschild, Hans Tesch, Mahdi Rezai, Tanja Fehm
Publikováno v:
New England Journal of Medicine. 366:299-309
Background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, m
Autor:
Michael Untch, Friedrich Overkamp, Minckwitz G von, V Müller, Eulenburg C zu, S Stirnberg, S. Loibl, A. Kohls, Iris Schrader, Tanja Fehm, A Abdallah, Thorsten Kühn, I Witzel, Christoph Uleer
Publikováno v:
Cancer Research. 71:P4-08
Background Neoadjuvant chemotherapy (NT) has become an important approach to assess therapeutic efficacy of new treatment strategies. We observed a predictive role of of serum HER2 (sHER2) with neoadjuvant trastuzumab treatment in the previous trial
Autor:
K. Schwedler, Hans Ulrich Ulmer, S Stirnberg, Antje Belau, K Kittel, Frank Holms, S. Loibl, Peter A. Fasching, Hans Tesch, H. Eidtmann, Christoph Salat, Iris Schrader, Valentina Nekljudova, Mahdi Rezai, Christine Mau, Minckwitz G von, Elmar Stickeler, A Abdallah
Publikováno v:
Cancer Research. 71:P1-14
Background: Bevacizumab has been reported to increase the risk of surgical complications, especially in pts treated with neoadjuvant chemotherapy. Methods: In January 2010 it was decided to collect surgical complications prospectively on a specifical
Autor:
Klaus Friese, V Müller, Mahdi Rezai, Wolfgang Janni, M. W. Beckmann, Hans Tesch, Julia Neugebauer, Brigitte Rack, C Dinkel, M. Kupka, Andreas Schneeweiss, Iris Schrader, U Söling
Publikováno v:
Cancer Research. 71:P5-14
Background: Premenopausal women undergoing chemotherapy are at risk of premature ovarian failure and long term side-effects caused by premature menopause. However, knowledge about the rate of ovarian failure and potential markers to evaluate the ovar
Autor:
Katharina Tiemann, G Hoffmann, Kurt Diebold, Carsten Denkert, S. Henschen, Frank Holms, Marianne Just, Michael R. Clemens, Klaus Dietrich, Jens Huober, Silvia Darb-Esfahani, Sibylle Loibl, Michael Untch, Christine Solbach, Holger Eidtmann, Gunter von Minckwitz, Iris Schrader, Claus Hanusch, Hans Tesch
Publikováno v:
Breast Cancer Research and Treatment. 132:863-870
Adjacent ductal carcinoma in situ (DCIS) is found in approximately 45% of invasive ductal carcinomas (IDC) of the breast. Pure DCIS overexpresses HER2 in approximately 45%. There is uncertainty whether adjacent DCIS impacts on the response to neoadju
Autor:
Andreas Schneeweiss, Christian Schindlbeck, Werner Lichtenegger, Thomas Zwingers, Wolfgang Janni, Hans Tesch, Julia Neugebauer, Harald Sommer, M. W. Beckmann, Klaus Friese, Brigitte Rack, Iris Schrader
Publikováno v:
Cancer Research. 70:P3-10
Background: While tumor markers are frequently used to assess treatment efficacy in metastatic breast cancer, there is lack of evidence regarding the role of MUC-1 markers in primary disease. The value of CA27.29 in the adjuvant setting was prospecti
Autor:
Kristina Luebbe, Karl-Heinz Noeding, Wulf Siggelkow, Iris Schrader, Christoph Busch, Peter Hillemanns, Thilo Dörk, Tjoung-Won Park-Simon, T Noesselt, Momme Arfsten, Regina Meier, Stefanie Noeding, Elna Kuehnle
Publikováno v:
Journal of Clinical Oncology. 36:e18650-e18650
e18650Background: Although immigrant health is an important issue in worldwide health policy there is a serious shortage of data in many countries, especially survival data. In this prospective cro...
Autor:
Manfred Dietel, Claus Hanusch, Berit Maria Müller, Jan Budczies, Marc Roller, Gunter von Minckwitz, Aurelia Noske, Wilko Weichert, Iris Schrader, Knut Engels, Christian von Törne, Ralf Kronenwett, Silvia Darb-Esfahani, Christine Solbach, Carsten Denkert, Martina Komor, Sibylle Loibl
Publikováno v:
Journal of Clinical Oncology. 28:105-113
Purpose Preclinical data suggest a contribution of the immune system to chemotherapy response. In this study, we investigated the prespecified hypothesis that the presence of a lymphocytic infiltrate in cancer tissue predicts the response to neoadjuv